Literature DB >> 11412217

Combined androgen blockade in prostate cancer: meta-analyses and associated issues.

L Klotz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11412217     DOI： 10.1046/j.1464-410x.2001.02184.x

Source DB:  PubMed          Journal:  BJU Int        ISSN： 1464-4096            Impact factor:   5.588


× No keyword cloud information.
  9 in total

1.  Maximum androgen blockade: a clinical update.

Authors:  Gerald W Chodak
Journal:  Rev Urol       Date:  2005

2.  A critical review of maximal androgen blockade for advanced prostate cancer.

Authors:  Gerald W Chodak
Journal:  Rev Urol       Date:  2004

Review 3.  Bicalutamide: clinical pharmacokinetics and metabolism.

Authors:  Ian D Cockshott
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

4.  Impact of androgen deprivation therapy on racial/ethnic disparities in the survival of older men treated for locoregional prostate cancer.

Authors:  Laurens Holmes; Wenyaw Chan; Zhidong Jiang; Doriel Ward; E James Essien; Xianglin L Du
Journal:  Cancer Control       Date:  2009-04       Impact factor: 3.302

5.  Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community-based multi-institutional database across Japan using propensity score matching.

Authors:  Mizuki Onozawa; Hideyuki Akaza; Shiro Hinotsu; Mototsugu Oya; Osamu Ogawa; Tadaichi Kitamura; Kazuhiro Suzuki; Seiji Naito; Mikio Namiki; Kazuo Nishimura; Yoshihiko Hirao; Taiji Tsukamoto
Journal:  Cancer Med       Date:  2018-08-27       Impact factor: 4.452

6.  Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database.

Authors:  Jennifer L Beebe-Dimmer; Julie J Ruterbusch; Lauren C Bylsma; Christina Gillezeau; Jon Fryzek; Neil M Schultz; Scott C Flanders; Arie Barlev; Elisabeth Heath; Ruben G W Quek
Journal:  Adv Ther       Date:  2018-06-26       Impact factor: 3.845

7.  Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004.

Authors:  Sabina Hussain; David Gunnell; Jenny Donovan; Sean McPhail; Freddie Hamdy; David Neal; Peter Albertsen; Julia Verne; Peter Stephens; Caroline Trotter; Richard M Martin
Journal:  BJU Int       Date:  2008-01-10       Impact factor: 5.588

Review 8.  Adjuvant hormone therapy after radiation or surgery for localized or locally advanced prostate cancer.

Authors:  William A See
Journal:  Curr Treat Options Oncol       Date:  2003-10

9.  Maximal androgen blockade for the treatment of metastatic prostate cancer--a systematic review.

Authors:  H Lukka; T Waldron; L Klotz; E Winquist; J Trachtenberg
Journal:  Curr Oncol       Date:  2006-06       Impact factor: 3.677
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.